Vincent De Biasi, Jr MBA
About Vincent De Biasi, Jr MBA
Vincent De Biasi, Jr MBA is the Director of Program Management at Bristol Myers Squibb in New Brunswick, New Jersey, with extensive experience in the pharmaceutical industry, including roles at Novartis, Pfizer, and Wyeth Biotech.
Title
Vincent De Biasi, Jr., MBA is the Director of Program Management at Bristol Myers Squibb, located in New Brunswick, New Jersey, United States.
Company
Vincent currently works at Bristol Myers Squibb as the Director of Program Management. His role includes creating and optimizing cross-functional processes and systems on a global scale.
Past Roles at Novartis
Vincent worked at Novartis in several capacities. He was the Director from 2018 to 2021, and prior to that, he served as Associate Director from 2014 to 2018. Before becoming Associate Director, he held the position of Associate Director, Technical Transfer for nine months from 2013 to 2014. His roles were all in North America.
Career at Pfizer and Wyeth Biotech
Vincent's tenure at Pfizer included roles such as Manager, Tech Dev Services (2012-2013) in Pearl River, NY, and Principle Project Manager I (2009-2012). He worked at Wyeth Biotech as Sr. Project Manager (2007-2008), Manager (2004-2007), and held various other roles from 1998 to 2004.
Education and Expertise
Vincent holds a Master of Business Administration (MBA) in Information Technology from IONA and a Bachelor of Science (BS) in Chemical Engineering from the New Jersey Institute of Technology. He also studied Lean Six Sigma at Rath & Strong, where he was a Green Belt candidate.
Specialized Experience
Vincent has extensive experience in sterile, biologics, solid dosage, and cell and gene therapies. He applies tools from Lean Six Sigma, Agile, and traditional project management to ensure modern and mature operational approaches. His efforts are geared toward establishing clear performance measures and a culture of accountability.
Project Leadership
One notable project led by Vincent was the Serialization program for ESO Americas at Novartis. This initiative was a critical importance and demonstrated his ability to design and deliver innovative projects successfully.